Efficacy and Safety of Tapentadol ER for Diabetic Peripheral Neuropathic Pain: Results of a Randomized-Withdrawal, Double-Blind, Placebo-Controlled Phase III Study

被引：0
|
作者：
Etropolski, Mila
Shapiro, Douglas
Okamoto, Akiko
Rauschkolb-Loeffler, Christine
Haeussler, Juergen
机构：
来源：
NEUROLOGY | 2009年 / 72卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A217 / A218
页数：2
相关论文
共 50 条
  • [31] A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain
    Wallace, MS
    Rowbotham, MC
    Katz, NP
    Dworkin, RH
    Dotson, RM
    Galer, BS
    Rauck, RL
    Backonja, MM
    Quessy, SN
    Meisner, PD
    NEUROLOGY, 2002, 59 (11) : 1694 - 1700
  • [32] Efficacy and safety of itopride in functional dyspepsia: Results of two phase III multicentre, randomized, double-blind, placebo-controlled trials
    Talley, Nicholas J.
    Tack, Jan
    Ptak, Theadore
    Gupta, Rajendra
    Giguere, Monique
    GASTROENTEROLOGY, 2007, 132 (04) : A93 - A93
  • [33] A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL OF IVIG 10% IN PATIENTS WITH DERMATOMYOSITIS. THE PRODERM STUDY: RESULTS ON EFFICACY AND SAFETY
    Aggarwal, R.
    Charles-Schoeman, C.
    Schessl, J.
    Bata-Csorgo, Z.
    Dimachkie, M.
    Griger, Z.
    Moiseev, S.
    Oddis, C. V.
    Schiopu, E.
    Vencovsky, J.
    Beckmann, I.
    Levine, T.
    Clodi, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 4 - 5
  • [34] Efficacy of oral mexiletine for neuropathic pain with allodynia: A double-blind, placebo-controlled, crossover study
    Wallace, MS
    Magnuson, S
    Ridgeway, B
    REGIONAL ANESTHESIA AND PAIN MEDICINE, 2000, 25 (05) : 459 - 467
  • [35] GLANCE Results of a phase 2, randomized, double-blind, placebo-controlled study
    Goodman, A. D.
    Rossman, H.
    Bar-Or, A.
    Miller, A.
    Miller, D. H.
    Schmierer, K.
    Lublin, F.
    Khan, O.
    Bormann, N. M.
    Yang, M.
    Panzara, M. A.
    Sandrock, A. W.
    NEUROLOGY, 2009, 72 (09) : 806 - 812
  • [36] Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial
    Attal, Nadine
    de Andrade, Daniel C.
    Adam, Frederic
    Ranoux, Daniele
    Teixeira, Manoel J.
    Galhardoni, Ricardo
    Raicher, Irina
    Ueceyler, Nurcan
    Sommer, Claudia
    Bouhassira, Didier
    LANCET NEUROLOGY, 2016, 15 (06): : 555 - 565
  • [37] Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study
    Dogra, Sunil
    Krupashankar
    Budamakuntla, Leelavathy
    Srinivas, C. R.
    Khopkar, Uday
    Gupta, Sandesh
    Shetty, Narendra
    Pratap, Dasiga Venkata Subrahmanya
    Gopal, M. G.
    Rao, T. Narayana
    Garg, Vijay
    Sumathy, T. K.
    Saraswat, Abir
    Bhat, Ramesh
    Kura, Mahendra
    Pandey, Neeraj
    Shah, Radha
    Krishna, Kotla Sai
    Padmaja, Dalavai
    Manmohan, G.
    Ramakrishnan, M. S.
    Barve, Abhijit
    Montero, Enrique
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (02) : 331 - 333
  • [38] Tanezumab Reduces Osteoarthritic Hip Pain Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial
    Brown, Mark T.
    Murphy, Frederick T.
    Radin, David M.
    Davignon, Isabelle
    Smith, Michael D.
    West, Christine R.
    ARTHRITIS AND RHEUMATISM, 2013, 65 (07): : 1795 - 1803
  • [39] Tanezumab Reduces Osteoarthritic Knee Pain: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial
    Brown, Mark T.
    Murphy, Frederick T.
    Radin, David M.
    Davignon, Isabelle
    Smith, Michael D.
    West, Christine R.
    JOURNAL OF PAIN, 2012, 13 (08): : 790 - 798
  • [40] A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment
    Serpell, M.
    Ratcliffe, S.
    Hovorka, J.
    Schofield, M.
    Taylor, L.
    Lauder, H.
    Ehler, E.
    EUROPEAN JOURNAL OF PAIN, 2014, 18 (07) : 999 - 1012
12345